Back to search results

Revaree Plus for Vaginal Dryness in Breast Cancer Patients

This study is testing Revaree Plus, a hyaluronic acid vaginal suppository, to see if it can improve vaginal dryness for people undergoing breast cancer treatment. You may be able to join if you are an adult woman (18 years or older) with Stage 0-3 hormone-receptor positive breast cancer who has completed primary treatment or is on maintenance therapy, and is currently taking an aromatase inhibitor. The study will measure changes in vaginal health using a special scale over 8 weeks to see if Revaree Plus is effective. The current status of this study is unclear, but it plans to enroll 60 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 8 weeks, indicating participants will be followed for at least this long after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07042581

A Study of Revaree Plus in People With Breast Cancer

Recruiting
PHASE4Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~60 participants
Updated 2026-02-06 on ClinicalTrials.gov
What's tested:Revaree Plus

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Vaginal Assessment Scale from baseline to 8 weeks
Measured over 8 weeks

Conditions

Breast Cancer
Stage 0 Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Stage 0 Breast Carcinoma
Stage II Breast Carcinoma
Stage III Breast Carcinoma
Hormone-receptor-positive Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Hormone Receptor Positive Malignant Neoplasm of Breast

Explore related trials

Breast CarcinomaHR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Shari Goldfarb, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Shari Goldfarb, MD
[email protected]
646-888-5080
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥18 years of age at the time of signing informed consent.
Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC
Able to complete study questionnaires in English or Spanish
Breast cancer patients must have completed primary therapy (surgery, and/or chemotherapy, and/or radiation therapy) or currently on maintenance therapy
Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM)
Currently have no clinical evidence of disease
Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\])
A total score of 4 or greater in VAS
Without history of other cancers (excluding non-melanoma skin cancer)
Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study

Exclusion

Inability to provide informed consent
Vaginal bleeding of unknown etiology within 12 months of study entry
Currently taking hormone replacement therapy \[local or systemic\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
No known allergies to any ingredients in 10mg HLA suppository

What this trial measures

  • Change in Vaginal Assessment Scale from baseline to 8 weeks8 weeks

    The primary study objective is to evaluate whether vaginal health improves from baseline to 8 weeks of treatment with Revaree Plus as measured by the Vaginal Assessment Scale